1. Home
  2. CLGN vs RGNT Comparison

CLGN vs RGNT Comparison

Compare CLGN & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

N/A

Current Price

$0.63

Market Cap

18.4M

Sector

Health Care

ML Signal

N/A

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$3.36

Market Cap

20.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLGN
RGNT
Founded
2004
2004
Country
Israel
Israel
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
20.4M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
CLGN
RGNT
Price
$0.63
$3.36
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
99.5K
6.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1,596.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$3.10
52 Week High
$4.98
$8.35

Technical Indicators

Market Signals
Indicator
CLGN
RGNT
Relative Strength Index (RSI) 34.59 29.72
Support Level $0.50 N/A
Resistance Level $1.60 $4.40
Average True Range (ATR) 0.08 0.30
MACD 0.04 0.01
Stochastic Oscillator 63.40 16.94

Price Performance

Historical Comparison
CLGN
RGNT

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Share on Social Networks: